BackMoonLake Immunotherapeutics Overview

MoonLake Immunotherapeutics Minority Interest

Latest minority interest for MLTX: $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00
↓ 100.00% YoYΔ $-4.21M vs prior year quarter

Peer trimmed avg / median

Loading

MoonLake Immunotherapeutics Minority Interest History

Loading

MoonLake Immunotherapeutics vs. peers: Minority Interest Comparison

Loading

MoonLake Immunotherapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

MoonLake Immunotherapeutics (MLTX) FAQ

MoonLake Immunotherapeutics (MLTX) currently reports a minority interest of $0 as of June 2026. That compares with $4.2M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore MoonLake Immunotherapeutics's minority interest history and peer comparisons.

MoonLake Immunotherapeutics's minority interest decreased from $4.2M to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MoonLake Immunotherapeutics reported $0 in minority interest as of June 2026. That compares with $4.2M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current minority interest of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MoonLake Immunotherapeutics, and consider following MLTX for alerts when major investors trade the stock.